RBC Capital raised the firm’s price target on Incyte (INCY) to $84 from $81 and keeps a Sector Perform rating on the shares after its Q3 earnings beat. The company’s solid commercial performance for Jakafi and Opzelura, along with newly launched products such as Niktimvo, provided additional tailwinds for a top/bottom line beat, reassuring on its base business, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY: